Carboplatin

Overview

Carboplatin is a chemotherapy medication used to treat various types of cancer. It is a platinum-based compound that interferes with the DNA of cancer cells, inhibiting their growth and division.

API suppliers (16)

Suppliers of Carboplatin evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• UMICORE ARGENTINA SA1 active DMF
• HERAEUS PRECIOUS METALS GMBH AND CO KGGermany1 active DMF
• TAPI NL BVNetherlands1 active DMF
• Qilu Pharmaceutical Co., Ltd.China1 active DMF GMP on record
• Hetero Labs LimitedIndia1 active DMF GMP on record
• KUNMING GUIYAN PHARMACEUTICAL CO LTDChina1 active DMF
• Laurus Labs LimitedIndia1 active DMF GMP on record
• VERANOVA LPUnited Kingdom1 active DMF
• Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
• MAC CHEM PRODUCTS INDIA PVT LTD GMP on record
• LACHEMA BRNO
• FRESENIUS KABI ONCOLOGY LTDIndia GMP on record
• Cipla LimitedIndiaCEP GMP on record
• PLIVA-LACHEMA AS
• INSTITUTE DRUG TECHNOLOGY AUSTRALIA LTD
• Cipla USA, Inc.USA

EU CEP holders (10)

Companies holding a valid EU Certificate of Suitability (CEP) for Carboplatin, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.

Patent & exclusivity (US)

Per the FDA Orange Book (43 approved US products), the latest listed US patent on Carboplatin expires 1 Apr 2045. Generic API sourcing typically opens up once these lapse.

Therapeutic areas